替格瑞洛联用瑞舒伐他汀治疗急性心肌梗死的效果观察

Abstract: Objective To investigate the efficacy of combining ticagrelor and rosuvastatin in the treatment of acute myocardial infarction. Methods Patients with acute myocardial infarction were selected between February 2020 and November 2024, with a total of 120 cases enrolled. They were randomly divided into two groups using a random number table method, with 60 cases in each group. The control group received rosuvastatin monotherapy, while the observation group received rosuvastatin combined with ticagrelor. The differences in efficacy, hemodynamic parameters, and cardiac function indicators between the two groups were compared. Results Between-group comparisons showed that the observation group had a higher effective rate (P＜0.05). When comparing intergroup mean pressure differences (mMVP), mean left atrial pressure (mLAP), and mean pulmonary artery pressure (mPAP), there were no significant differences before treatment (P＞0.05). However, after treatment, the observation group had lower levels of these indicators (P＜0.05). When comparing the left ventricular end-diastolic diameter (LVEDD), cardiac output (CO), 6-minute walk distance (6MWD), interventricular septal thickness (IVST), stroke volume (SV), left ventricular ejection fraction (LVEF), and left ventricular end-systolic diameter (LVESD) between groups, there were no significant differences before treatment (P＞0.05). After treatment, compared with the control group, the observation group had lower LVEDD, IVST, and LVESD, and higher 6MWD, CO, SV, and LVEF (P＜0.05). Conclusion Ticagrelor combined with rosuvastatin has a relatively significant effect on acute myocardial infarction.